Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $3.33 Average Price Target from Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $3.3333.

A number of analysts recently issued reports on RVPH shares. Chardan Capital reiterated a “buy” rating and set a $2.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter valued at about $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals during the third quarter valued at approximately $37,000. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the first quarter valued at approximately $58,000. Geode Capital Management LLC grew its stake in Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares in the last quarter. Finally, Persistent Asset Partners Ltd increased its holdings in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after buying an additional 480,864 shares during the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Trading Up 0.3%

Shares of RVPH stock opened at $0.30 on Wednesday. The firm’s 50 day moving average is $0.45 and its 200 day moving average is $0.47. The stock has a market capitalization of $34.85 million, a P/E ratio of -0.66 and a beta of 0.08. Reviva Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $2.15.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. On average, equities analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.